FrancophonIA/ELRC3.0 huggingface dataset:
English: During its September 2005 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Lansoprazol CT-Arzneimittel.
Estonian: Tuginedes kõigile esitatud andmetele ja komitee sisesele arutelule, jõudis inimtervishoius kasutatavate ravimite komitee oma 2005. aasta septembri koosolekul seisukohale, et Lansoprazol CT-Arzneimitteli riski ja kasu vahekord on soodne.
English: Lansoprazol CT-Arzneimittel (lansoprazole) is a proton pump inhibitor that inhibits gastric acid secretion and is used for treatment of duodenal and gastric ulcer, reflux oesophagitis, gastrooesophageal reflux disease, treatment and prophylaxis of NSAID-associated gastric and duodenal ulcers, Zollinger-Ellison syndrome, and in combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori and prevention of relapse of peptic ulcers in patients with H. pylori associated ulcers.
Estonian: Lansoprasooli kasutatakse kaksiksõrmiksoole ja maohaavandite, refluksösofagiidi, gastroösofageaalse reflukshaiguse raviks, mittesteroidsete põletikuvastaste ravimitega seotud mao- ja kaksteistsõrmikuhaavandite ja Zollinger-Ellisoni sündroomi raviks ja profülaktikaks.
English: Powder for concentrate for solution for infusion
Estonian: Manustamistee Sisepakendi iseloomustus
English: Further information on Aranesp can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/aranesp.
Estonian: Lisateave Aranespi kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/aranesp.
English: What measures are being taken to ensure the safe and effective use of Aranesp?
Estonian: Mis meetmed võetakse, et tagada Aranespi ohutu ja efektiivne kasutamine?
English: The European Medicines Agency decided that Aranesp's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Aranespi kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: Aranesp received a marketing authorisation valid throughout the EU on 8 June 2001.
Estonian: Aranespi müügiluba, mis kehtib kogu Euroopa Liidus, anti 8. juunil 2001.
English: Aranesp (darbepoetin alfa) EMA/183281/2019
Estonian: Aranesp (alfadarbepoetiin) EMA/183281/2019
English: Aranesp (darbepoetin alfa)
Estonian: Aranesp (alfadarbepoetiin)
English: In two studies involving 669 patients receiving chemotherapy, Aranesp was more effective than placebo (a dummy treatment) and fewer patients needed a blood transfusion.
Estonian: Kahes uuringus, milles osales 669 keemiaravi saavat patsienti, oli Aranesp efektiivsem kui platseebo (näiv ravim) ja vähem patsiente vajas vereülekannet.
English: What is Aranesp and what it is used for?
Estonian: Mis on Aranesp ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Aranesp are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Aranespi kasutamise kohta pidevat järelevalvet.
English: It is used in two groups of patients:
Estonian: Aranespi kasutatakse kahes patsiendirühmas:
English: Aranesp has also been studied in 124 children with chronic renal failure to check that it is absorbed in the same way as in adults.
Estonian: Aranespi uuriti ka 124 kroonilise neerupuudulikkusega lapsel, et kontrollida, kas see imendub samamoodi nagu täiskasvanutel.
English: Side effects reported with Aranesp are carefully evaluated and any necessary action taken to protect patients.
Estonian: Aranespi kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For the full list of side effects and restrictions, see the package leaflet
Estonian: Kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: The lowest dose that provides adequate control of symptoms should be used.
Estonian: Kasutada tuleb kõige väiksemat annust, mis leevendab sümptomeid piisavalt.
English: The company that markets Aranesp will provide educational packs for patients and healthcare professionals including information on how to self-inject the medicine, a training checklist and a demonstration device.
Estonian: Aranespi turustaja annab patsientidele ja tervishoiutöötajatele teabematerjalid, sealhulgas teabe, kuidas ravimit ise süstida, väljaõppe kontroll-loendi ja näidisvahendi.
English: Aranesp must not be used in patients who have poorly controlled high blood pressure.
Estonian: Aranespi ei tohi kasutada patsiendid, kellel kõrge vererõhk allub halvasti ravile.
English: • adults and children with chronic renal failure (long-term, decreasing in the ability of the kidneys to work properly);
Estonian: • täiskasvanud ja lapsed, kellel on krooniline neerupuudulikkus (neerutalitluse pikaajaline häire);
English: In kidney failure patients, the most common side effects with Aranesp (which may affect more than 1 in 10 people) are hypersensitivity (allergy) and hypertension (high blood pressure) while in cancer patients the most common are hypersensitivity and oedema (fluid retention).
Estonian: Neerupuudulikkusega patsientidel on Aranespi kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) ülitundlikkus (allergia) ja hüpertensioon (kõrge vererõhk); vähipatsientidel on kõige sagedamad ülitundlikkus ja turse (vedelikupeetus).
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Aranesp have also been included in the summary of product characteristics and the package leaflet.
Estonian: Aranespi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Other information about Aranesp
Estonian: Muu teave Aranespi kohta
English: Aranesp was as effective as human recombinant erythropoietin at increasing the haemoglobin levels and at keeping these levels maintained, whether given as an injection into a vein or under the skin.
Estonian: Aranesp oli sama efektiivne kui inimese rekombinantne erütropoetiin hemoglobiinisisalduse suurendamisel ja selle taseme säilitamisel, olenemata sellest, kas seda süstitakse veeni või naha alla.
English: Aranesp has been shown to be effective in the treatment of chronic renal failure in four studies involving over 1,200 patients.
Estonian: Aranespi efektiivsus kroonilise neerupuudulikkuse ravis on tõendatud neljas uuringus, milles osales üle 1200 patsiendi.
English: • adults who are receiving chemotherapy for non-myeloid cancer (cancer not originating in the bone marrow).
Estonian: • täiskasvanud, kellel ravitakse mittemüeloidset (mujalt kui luuüdist alanud) vähki keemiaraviga.
English: The dose and frequency of injection depend on why Aranesp is being used, and are adjusted, according to the patient's response, to obtain haemoglobin levels that remain within the recommended range (between 10 and 12 grams per decilitre).
Estonian: Annus ja süstimissagedus sõltuvad Aranespi kasutamise põhjusest ning neid kohandatakse patsiendi reaktsiooni järgi, et saavutada hemoglobiinisisaldus soovitatavas vahemikus (10-12 g/dl).
English: For more information about using Aranesp, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Aranespi kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Aranesp can be injected by the patient or their carer if they have been trained.
Estonian: Aranespi tohib süstida patsient või tema hooldaja, kui nad on saanud asjakohase väljaõppe.
English: What are the risks associated with Aranesp?
Estonian: Mis riskid Aranespiga kaasnevad?
English: In patients receiving chemotherapy or with kidney problems, anaemia can be caused by a lack of a hormone called erythropoietin, or by the body not responding well enough to erythropoietin.
Estonian: Keemiaravi saavatel või neeruhäiretega patsientidel võib aneemiat põhjustada hormooni erütropoetiini vaegus või organismi ebapiisav reageerimine erütropoetiinile.
English: Aranesp can only be obtained with a prescription and treatment should be started by a doctor who has experience in treating the types of anaemia mentioned above.
Estonian: Aranesp on retseptiravim ja ravi peab alustama eespool nimetatud aneemiatüüpide ravis kogenud arst.
English: The active substance in Aranesp, darbepoetin alfa works in exactly the same way as the natural hormone to stimulate the production of red blood cells in the bone marrow.
Estonian: Aranespi toimeaine alfadarbepoetiin toimib täpselt samamoodi kui looduslik hormoon, stimuleerides erütrotsüütide tootmist luuüdis.
English: What benefits of Aranesp have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Aranespi kasulikkus?
English: For patients with chronic renal failure, Aranesp can be injected into a vein or under the skin.
Estonian: Kroonilise neerupuudulikkusega patsientidel süstitakse Aranespi veeni või naha alla.
English: An overview of Aranesp and why it is authorised in the EU
Estonian: Ülevaade ravimist Aranesp ja ELis müügiloa väljastamise põhjendus
English: Aranesp is a medicine used to treat anaemia (low red blood cell counts) that is causing symptoms.
Estonian: Aranesp on ravim, mida kasutatakse sümptomeid põhjustava aneemia raviks.
English: How is Aranesp used?
Estonian: Kuidas Aranespi kasutatakse?
English: Aranesp is available in a vial, a pre-filled syringe or a pre-filled pen.
Estonian: Aranespi turustatakse viaalis, eeltäidetud süstlas või eeltäidetud pensüstlas ning eri tugevustes.
English: Because of the slight changes to the structure, darbepoetin alfa remains in the body for longer than natural erythropoietin.
Estonian: Alfadarbepoetiinil on veidi teistsugune struktuur kui looduslikul hormoonil, mistõttu püsib alfadarbepoetiin organismis kauem kui looduslik erütropoetiin.
English: Aranesp contains the active substance darbepoetin alfa.
Estonian: Ravim sisaldab toimeainena alfadarbepoetiini.
English: It must be injected under the skin in patients receiving chemotherapy.
Estonian: Keemiaravi saavatel patsientidel süstitakse Aranespi naha alla.
English: This summary was last updated on 6 January 2012.
Estonian: Kokkuvõtte viimane uuendus: 6. jaanuaril 2012.
English: ProMeris Duo metaflumizone and amitraz
Estonian: ProMeris Duo metaflumisooni ja amitrazi
English: Demodicosis was usually cured within three to six months of treatment.
Estonian: Demodikoos paranes tavaliselt 3-6 kuu jooksul pärast ravi.
English: These usually disappear without treatment within 24 hours.
Estonian: Need kõrvalnähud kaovad tavaliselt ilma ravita 24 tunni jooksul.
English: The European Commission granted a marketing authorisation valid throughout the European Union for ProMeris Duo on 19 December 2006.
Estonian: Euroopa Komisjon andis ProMeris Duo müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 19. detsembril 2006.
English: Amitraz is a monoamine oxidase inhibitor (MOAI).
Estonian: Amitraas on monoaminooksüdaasi inhibiitor (MOAI).
English: In very rare cases, temporary local hair loss may occur.
Estonian: Väga harvadel juhtudel võib esineda paikset ajutist karvade väljalangemist.
English: This medicine is specifically developed for dogs and should not be used in any other animal species.
Estonian: Ravim on välja töötatud spetsiaalselt koertele ja seda ei tohi kasutada ühelgi muul loomaliigil.
English: Recently treated animals should not be allowed to sleep in the same bed as their owners, especially children.
Estonian: Äsja ravimit saanud loom ei tohi magada koos omanikuga ja eelkõige lastega samas voodis.
English: Protective gloves are recommended when handling the medicine.
Estonian: Ravimi kasutamisel soovitatakse kanda kaitsekindaid.
English: It is recommended that the product is applied in the open air or in a well-ventilated room.
Estonian: Ravimit soovitatakse manustada väljas või hästi ventileeritud toas.
English: ProMeris Duo must not be used in puppies less than eight weeks old since it has not been sufficiently studied in these animals.
Estonian: ProMeris Duot ei tohi kasutada alla 8-nädalastel kutsikatel, sest seda ravimit ei ole neil loomadel piisavalt uuritud.
English: People taking MOAI-containing medicines, such as antidepressants, should take particular care when handling ProMeris Duo.
Estonian: Neid sisaldavaid ravimeid, näiteks antidepressante kasutavad inimesed peavad olema ProMeris Duo tarvitamisel eriti ettevaatlikud.
English: As a precautionary measure, avoid direct contact with the treated dog and do not allow children to play with the treated dog until the application site is dry.
Estonian: Ettevaatusmeetmena vältige vahetut kokkupuudet ravimit saava koeraga ning ärge lubage lastel sellise loomaga mängida, kuni manustamiskoht on kuiv.
English: The medicine killed most fleas within 24 hours, most ticks within 48 hours and most lice within a week of treatment.
Estonian: Ravim hävitas enamiku kirpudest 24 tunni, enamiku puukidest 48 tunni ja enamiku täidest ühe nädala jooksul pärast manustamist.
English: ProMeris Duo contains components that, on very rare occasions, can irritate the airways in some people.
Estonian: ProMeris Duo sisaldab komponente, mis võivad mõnel inimesel väga harvadel juhtudel tekitada ärritust hingamisteedes.
English: ProMeris Duo should not enter surface water, as this may be harmful for fish and other aquatic organisms.
Estonian: ProMeris Duo ei tohi sattuda pinnavette, sest see võib olla ohtlik kaladele ja teistele veeorganismidele.
English: It is given to dogs with a pre-filled spot-on pipette, a small plastic container that is already filled with the correct amount of ProMeris Duo needed to treat one dog.
Estonian: Seda manustatakse koertele täpilahusega eeltäidetud pipetiga, st väikese plastmahutiga, mis on täidetud ühe koera ravimiseks vajaliku ProMeris Duo kogusega.
English: The Committee recommended that ProMeris Duo be given a marketing authorisation.
Estonian: Komitee soovitas anda ProMeris Duole müügiloa.
English: The most common side effects in dogs are sedation (sleepiness), lethargy (a lack of energy), reduced nervous system activity, hyperglycaemia (high blood sugar levels), bradycardia (slow heart rate), and slow, shallow breathing.
Estonian: Koerte kõige sagedamad kõrvalnähud on sedatsioon (uimasus), loidus, närvisüsteemi alatalitlus, hüperglükeemia (suur glükoosisisaldus veres), bradükardia (südameaeglus), aeglane ja pinnapealne hingamine.
English: In rare cases, temporary irritation may occur at the site of application.
Estonian: Harvadel juhtudel võib manustamiskohal esineda mööduvat ärritust.
English: It can also be used as part of a treatment strategy for the control of flea allergy dermatitis, an allergic reaction to flea bites.
Estonian: Seda võib samuti kasutada kirbuallergiast põhjustatud dermatiidi (allergiline reaktsioon kirbuhammustuste vastu) ravi osana.
English: Data were provided on pharmaceutical quality, the safety of the medicine in dogs and its safety in humans (people who come into contact with the medicine) and in the environment.
Estonian: Esitati andmed ravimi farmatseutilise kvaliteedi kohta, ravimi ohutuse kohta nii koertel kui ka inimestel (ravimiga kokkupuutuvatel inimestel) ning keskkonnaohutuse kohta.
English: Avoid touching the skin with the pipette's contents.
Estonian: Vältige pipeti sisu sattumist nahale.
English: Another study was carried out in dogs with demodicosis in veterinary practices in Italy and Albania.
Estonian: Täiendav uuring korraldati Itaalia ja Albaania loomakliinikutes demodikoosiga koertel.
English: The effectiveness of ProMeris Duo lasted for at least six weeks against fleas and for four weeks against ticks.
Estonian: ProMeris Duo kirbuvastane toime kestis vähemalt kuus nädalat ja puugivastane toime neli nädalat.
English: Do not smoke, eat or drink when applying ProMeris Duo.
Estonian: ProMeris Duo manustamise ajal ärge suitsetage, sööge ega jooge.
English: Other information about ProMeris Duo:
Estonian: Muu teave ProMeris Duo kohta
English: As for other products in this group, ProMeris Duo should not be used in sick dogs, dogs that have just recovered from an illness or dogs that are suffering from heat stress.
Estonian: Nagu teisigi selle rühma ravimeid, ei tohi ProMeris Duot kasutada haigetel või äsja paranenud koertel ega kuumastressis olevatel koertel.
English: This means that it will kill parasites that live on or in the skin or in the fur of animals, such as fleas, ticks, lice and Demodex mites (mites that cause demodicosis or ‘mange').
Estonian: See tähendab, et ravim hävitab parasiidid, kes elavad looma karvades, naha peal või selle sees, nagu kirbud, puugid, täid ja täid ja vagellestad (Demodex; põhjustavad demodikoosi).
English: Why has ProMeris Duo been approved?
Estonian: Miks ProMeris Duo heaks kiideti?
English: Both active substances in ProMeris Duo, metaflumizone and amitraz, interfere with the neural activity of the parasites and consequently lead to their death.
Estonian: ProMeris Duo toimeained metaflumisoon ja amitraas häirivad mõlemad parasiitide närvitalitlust ja lõpuks hävitavad need.
English: The effectiveness of ProMeris Duo against flea, lice and tick infestations and Demodex mites has been studied in a number of studies, including one study in dogs infested with fleas or ticks carried out at veterinary practices in Germany and France.
Estonian: ProMeris Duo efektiivsust kirpude, täide, puukide ja vagellestade hävitamisel ja tõrjes uuriti mitmes uuringus, sealhulgas ühes, mis korraldati Saksamaa ja Prantsusmaa loomakliinikutes kirpude või puukidega koertel.
English: Dogs were treated with ProMeris Duo or the combination of imidacloprid and moxidectin (another medicine authorised in the EU for this indication).
Estonian: Koeri raviti kas ProMeris Duoga või imidaklopriidi ja moksidektiiniga (selleks näidustuseks Euroopa Liidus samuti heaks kiidetud ravimid).
English: If a dog licks the application area, the dog might salivate considerably for a short period.
Estonian: Kui koer lakub ravimi manustamiskohta, võib sellele järgneda lühiajaline tugev süljevool.
English: The contents of the pipette are squeezed onto the skin after parting the fur at the back of the head.
Estonian: Pipeti sisu pigistatakse nahale, olles eelnevalt lükanud koera kuklakarvad laiali.
English: The effectiveness was measured by looking at the number of lice on the dogs after treatment.
Estonian: Efektiivsust mõõdeti koertel pärast ravi leitud täide arvu alusel.
English: ProMeris Duo is available in five different sizes for various weights of dog.
Estonian: ProMeris Duot turustatakse vastavalt koera suurusele viies eri koguses.
English: ProMeris Duo is a clear, yellow-to-amber solution that contains metaflumizone and amitraz as active substances.
Estonian: Promeris Duot turustatakse selge kollaka või merevaigukarva lahusena, mis sisaldab toimeaineid metaflumisooni ja amitraasi.
English: ProMeris Duo is an ‘ectoparasiticide'.
Estonian: ProMeris Duo on ektoparasiitidevastane aine.
English: The effectiveness was measured looking at the number of live ticks or number of fleas on the dogs up to two months after application.
Estonian: Efektiivsust mõõdeti elus puukide või kirpude arvu alusel kuni kahe kuu jooksul pärast ravimi manustamist.
English: What is ProMeris Duo?
Estonian: Mis on ProMeris Duo?
English: What is the risk associated with ProMeris Duo?
Estonian: Mis riskid ProMeris Duoga kaasnevad?
English: Dogs of various breeds, ages and weights were treated with ProMeris Duo or with other medicines authorised in the European Union (EU) for flea and tick infestation.
Estonian: Eri tõugu, vanuses ja kaalus koeri raviti kas ProMeris Duo või muude Euroopa Liidus kirpude või puukide hävitamiseks näidustatud ravimitega.
English: A further study compared the effectiveness of ProMeris Duo with that of fipronil (another medicine for the treatment of lice).
Estonian: Lisauuringus võrreldi ProMeris Duo ja fiproniili (samuti täitõrjeravim) efektiivsust.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ProMeris Duo exceed the risks for the treatment and prevention of flea and tick infestations, and the treatment of demodicosis and lice infestation in dogs.
Estonian: Veterinaarravimite komitee jõudis järeldusele, et ProMeris Duo kasulikkus koertel kirpude ja puukide hävitamiseks ja tõrjeks ning täide hävitamiseks ja demodikoosi raviks ületab ravimiga kaasnevad riskid.
English: There may also be a change in appearance of the fur (oily appearance and clumping or spiking of hair) at the application site.
Estonian: Ravimi manustamiskohal võib muutuda karvkatte välimus (rasvasus ja pulstumine või karvade kokkukleepumine).
English: The results of the studies showed that ProMeris Duo is effective in the treatment and prevention of flea and tick infestations, and in the treatment of demodicosis and lice infestation in dogs.
Estonian: Uuringute tulemustest selgus, et ProMeris Duo on koertel kirpude ja puukide hävitamiseks ja tõrjeks ning täide hävitamiseks ja demodikoosi raviks efektiivne.
English: Wash the skin and rinse eyes with water, if accidental exposure occurs.
Estonian: Silma ja nahale sattumisel loputage silmi ja peske nahka veega.
English: The effectiveness was measured looking at the clinical signs and the number of Demodex mites in skin scrapings taken every four weeks, for several weeks following monthly administration of the treatment.
Estonian: Efektiivsust mõõdeti mitme nädala vältel pärast ravimi üks kord kuus manustamist kliiniliste nähtude põhjal ja iga nelja nädala järel nahakaape tulemusel leitud vagellestade arvu alusel.
English: ProMeris Duo is used in dogs over eight weeks of age to treat and to prevent tick and flea infestations, and to treat demodicosis (caused by Demodex mites) and lice infestations.
Estonian: ProMeris Duot kasutatakse üle kaheksa nädala vanustel koertel puukide ja kirpude hävitamiseks ja tõrjeks, täide hävitamiseks ja vagellestade põhjustatud demodikoosi raviks.
English: What is ProMeris Duo used for?
Estonian: Milleks ProMeris Duot kasutatakse?
English: How has ProMeris Duo been studied?
Estonian: Kuidas ProMeris Duot uuriti?
English: What benefit has ProMeris Duo shown during the studies?
Estonian: Milles seisneb uuringute põhjal ProMeris Duo kasulikkus?
English: How does ProMeris Duo work?
Estonian: Kuidas ProMeris Duo toimib?
English: Ref.: EMEA/280173/2009 EMEA/H/C/1016
Estonian: Viide: EMEA/480185/2009 EMEA/H/C/1016
English: It is available as brown tablets (250 mg).
Estonian: Seda turustatakse pruunide tablettidena (250 mg).
English: Iressa gefitinib EPAR summary for the public
Estonian: Iressa gefitiniib Kokkuvõte üldsusele
English: The European Commission granted a marketing authorisation valid throughout the European Union for Iressa to AstraZeneca AB on 24 June 2009.
Estonian: Euroopa Komisjon andis Iressa müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele AstraZeneca AB 24. juunil 2009.
English: The Committee recommended that Iressa be given marketing authorisation.
Estonian: Komitee soovitas anda Iressale müügiloa.
English: The main measure of effectiveness was how long the patients lived without the disease getting worse.
Estonian: Efektiivsuse põhinäitaja oli aeg, kui kaua patsiendid elasid ilma haiguse süvenemiseta.
English: The main measure of effectiveness was survival (how long the patients lived).
Estonian: Efektiivsuse põhinäitaja oli patsientide elulemus (aeg, kui kaua patsiendid elasid).
English: EGFR is involved in the growth and spread of cancer cells.
Estonian: EGFR osaleb vähirakkude kasvamisel ja levimisel.
English: In the first main study, Iressa was more effective at preventing the cancer from worsening than the combination.
Estonian: Esimeses põhiuuringus oli Iressa efektiivsus vähktõve süvenemise takistamisel suurem kui kombinatsioonravi korral.
English: Other information about Iressa:
Estonian: Muu teave Iressa kohta